New research published in Anesthesia & Analgesia suggests that new anesthetic agents currently in development could outperform traditional drugs, according to a Somnia Anesthesia blog post.
The first drug profiled, etomidate, has been improved by researchers at Massachusetts General Hospital. The researchers were able to improve the drug so that it does not interfere with the immune system, a current side effect of the agent.
The second, remimazolam, is a new benzodiazepine-type sedative drug with predictable effects and a comparatively rapid recovery time.
Improving Perioperative Efficiency, Quality Requires Nursing-Anesthesia Partnership
The first drug profiled, etomidate, has been improved by researchers at Massachusetts General Hospital. The researchers were able to improve the drug so that it does not interfere with the immune system, a current side effect of the agent.
The second, remimazolam, is a new benzodiazepine-type sedative drug with predictable effects and a comparatively rapid recovery time.
More Articles on Anesthesia:
FDA Approves Mylan's Generic Anesthesia Drug EtomidateImproving Perioperative Efficiency, Quality Requires Nursing-Anesthesia Partnership